{"id":"NCT02302807","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]","officialTitle":"A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01-13","primaryCompletion":"2017-03-13","completion":"2018-11-08","firstPosted":"2014-11-27","resultsPosted":"2018-04-11","lastUpdate":"2019-08-01"},"enrollment":931,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bladder Cancer"],"interventions":[{"type":"DRUG","name":"Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody","otherNames":["Tecentriq"]},{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Vinflunine","otherNames":[]}],"arms":[{"label":"Arm A: Atezolizumab","type":"EXPERIMENTAL"},{"label":"Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen. The anticipated time on study treatment is based on continued clinical benefit, i.e., until disease progression or unacceptable toxicity. The target sample size is 931 participants.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Between randomization and death due to any cause, up to approximately 25 months after first participant enrolled","effectByArm":[{"arm":"IC2/3 Chemotherapy","deltaMin":10.6,"sd":null},{"arm":"IC2/3 Atezolizumab","deltaMin":11.1,"sd":null},{"arm":"IC1/2/3 Chemotherapy","deltaMin":8.2,"sd":null},{"arm":"IC1/2/3 Atezolizumab","deltaMin":8.9,"sd":null},{"arm":"Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)","deltaMin":8,"sd":null},{"arm":"Atezolizumab","deltaMin":8.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4134"},{"comp":"OG002 vs OG003","p":null},{"comp":"OG004 vs OG005","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":16},"locations":{"siteCount":217,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","Italy","Japan","Netherlands","Norway","Poland","Portugal","Romania","Russia","Serbia","Slovenia","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["33902955","33241650","31542806","29562804","29268948","27939400","26454620"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":189,"n":443},"commonTop":["Constipation","Fatigue","Decreased Appetite","Nausea","Anaemia"]}}